(Q39388106)

English

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway (English)

1 reference

Europe PubMed Central

11 September 2017

11

1 reference

Europe PubMed Central

11 September 2017

Andreas Lackner

object named as

Andreas Lackner

4

0 references

Christine Pirker

object named as

Christine Pirker

6

0 references

object named as

Michael Grusch

3

0 references

Józefa Wesierska-Gadek

8

object named as

Józefa Węsierska-Gądek

1 reference

Europe PubMed Central

11 September 2017

author name string

Zsuzsanna Bago-Horvath

1

1 reference

Europe PubMed Central

11 September 2017

Wolfgang Sieghart

2

1 reference

Europe PubMed Central

11 September 2017

Hubert Hayden

5

1 reference

Europe PubMed Central

11 September 2017

Oxana Komina

7

1 reference

Europe PubMed Central

11 September 2017

Andrea Haitel

9

1 reference

Europe PubMed Central

11 September 2017

Martin Filipits

10

1 reference

Europe PubMed Central

11 September 2017

Katharina Schmid

12

1 reference

Europe PubMed Central

11 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

27 April 2012

1 reference

Europe PubMed Central

11 September 2017

Neuroendocrinology

1 reference

Europe PubMed Central

11 September 2017

96

1 reference

Europe PubMed Central

11 September 2017

3

1 reference

Europe PubMed Central

11 September 2017

228-237

1 reference

Europe PubMed Central

11 September 2017

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Activity of sunitinib in patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

In vivo activated caspase-3 cleaves PARP-1 in rat liver after administration of the hepatocarcinogen N-nitrosomorpholine (NNM) generating the 85 kDa fragment

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Epidermal growth factor receptor expression and activation in neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear β-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Phase II study of everolimus (RAD001) in previously treated small cell lung cancer

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Cytotoxic and biochemical effects of 3,3′,4,4′,5,5′-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1159%2F000337257

21 January 2018

Identifiers

10.1159/000337257

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39388106&oldid=1824593806"